C-059
Clozapine solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
grade
certified reference material
form
liquid
feature
SNAP-N-SPIKE®, SNAP-N-SHOOT®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24
InChI
1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
InChI key
QZUDBNBUXVUHMW-UHFFFAOYSA-N
Gene Information
human ... DRD2(1813) , HTR2A(3356)
General description
A Certified Snap-N-Spike® Solution for use in clinical toxicology, forensic analysis, or urine drug testing applications by LC/MS or GC/MS. Clozapine, sold as Clozaril® and FazaClo® in the US, is an atypical antipsychotic drug used for treatment of schizophrenia.
Application
- Augmentation Strategies for Clozapine Non-responders: A Bayesian network meta-analysis evaluated augmentation strategies for patients with schizophrenia who show partial or no response to clozapine, providing insights into effective secondary treatment options (Mishra et al., 2024).
- Antipsychotic Pre-treatment and Clozapine Metabolism: Research highlighted the impact of rapid metabolism of antipsychotics prior to clozapine treatment, affecting serum levels and suggesting a need for adjusted dosing strategies in treatment-resistant schizophrenia (Lenk HÇ et al., 2024).
- Genetic Influences on Clozapine Side Effects: A study identified polymorphisms in ERBB4 and TACR1 genes associated with dry mouth in patients treated with clozapine, pointing towards personalized management strategies for side effects (Puolakka et al., 2024).
- Therapeutic Mechanisms of Antipsychotics: An analysis focused on understanding the therapeutic mechanisms of antipsychotics including clozapine, examining cellular and molecular targets and their implications for optimizing treatment efficacy in psychiatric disorders (Direktor et al., 2024).
- Clozapine and Metabolic Syndrome in Schizophrenia: A study assessed the association between cytokine levels, psychopathology, and cognitive functions in clozapine-treated schizophrenia patients with metabolic syndrome, providing data critical for holistic treatment approaches (Dong et al., 2024).
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
FazaClo is a registered trademark of Jazz Pharmaceuticals International III Limited
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes,Central nervous system
Storage Class
3 - Flammable liquids
wgk_germany
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Chun-Hsin Chen et al.
The Journal of clinical psychiatry, 74(5), e424-e430 (2013-06-14)
Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia. Whether or not the beneficial effects can be sustained after discontinuation of metformin needs to be evaluated. We conducted a 24-week randomized
Saeko Ikai et al.
The Annals of pharmacotherapy, 47(7-8), e31-e31 (2013-06-13)
To report on a patient who was successfully rechallenged with clozapine after perforation of the large intestine and pulmonary embolism post operatively, and provide a literature review on clozapine rechallenge. A 46-year-old Japanese man with treatment-resistant schizophrenia developed constipation and
Benjamin W J Spencer et al.
Pharmacogenomics, 14(15), 1907-1914 (2013-11-19)
Clozapine is a uniquely efficacious antipsychotic drug in treatment-resistant schizophrenia. Its use is restricted due to adverse effects including a rare but dangerous reduction in neutrophils (agranulocytosis) and the mandatory hematological monitoring this entails in many countries. We review the
Rasmus Røge et al.
Schizophrenia research, 140(1-3), 204-213 (2012-07-27)
Clozapine remains the drug of choice for treatment resistant schizophrenia, but is associated with potentially life threatening side effects, including agranulocytosis and myocarditis. Immunological mechanisms may be involved in the development of these side effects or in the unique antipsychotic
Galvin Vredenburg et al.
Toxicology letters, 222(3), 247-256 (2013-08-07)
Clozapine, an often-prescribed antipsychotic drug, is implicated in severe adverse drug reactions (ADRs). Formation of reactive intermediates by cytochrome P450s (CYPs) has been proposed as a possible explanation for these ADRs. Moreover, a protective role for human glutathione S-transferases (hGSTs)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service